TET2 and acute myeloid leukemia: In conjunction with the paucity of large-scale DNA methylation changes in TET2 mutant AML patients, this critically challenges the current paradigm of mIDH-dependent DNA hypermethylation by D-2-HG-mediated TET inhibition.